8 down and 2 slightly up.
I'd love some thoughts on those coming milestones due in Q4 and how impactful they might be. Not knowing anything about these compounds or history, here are my thoughts:
ACP-044 for Acute pain phase 2 sounds high risk, but also high reward. I think pain drugs need multiple large trials and marketing budgets. I think any success would bring in big pharma for partnership or buyout.
Trofinetide Rett Syndrone phase 3, clinicaltrials.gov has a huge number of trials. What distinguishes this one?
The other one is the FDA meeting. A complete wild card. I doubt the share price gives this any value.